Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It

A business can look to be in solid shape but still not necessarily be a great investment overall. A good example of that is Viking Therapeutics (NASDAQ: VKTX). The company has been doing a lot of things well lately, and there's a lot of hope and optimism around the business.But all that may not be enough of a reason to invest in Viking Therapeutics. While the stock may look great to some investors right now, here's why it's not worth buying.The bullish case around Viking's stock has to do with a promising drug it has in development, which investors are hopeful may generate billions in revenue for the business in the long run. VK2735 is a glucagon-like peptide 1 (GLP-1) receptor agonist which has shown in clinical trials that it can help people lose as much as 15% of their body weight, on average. And the pill version has also been achieving promising results in early trials.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Zum vollständigen Artikel